Read more

March 09, 2023
11 min listen
Save

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of March 6, 2023

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

Read the full coverage here:

Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC

Global economic cost of cancer estimated to exceed $25 trillion over 30 years

Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Researchers develop AI model to accelerate radiation therapy planning for lung cancer

Asian, Black patients with lung cancer face longer wait times to radiation treatment

References:

Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826.

Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7.

Press Release

Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104

Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.

Sources/Disclosures

Collapse

Disclosures: Please see each study for relevant financial disclosures.